Compare · DXCM vs PLSM
DXCM vs PLSM
Side-by-side comparison of DexCom Inc. (DXCM) and Pulsenmore Ltd. (PLSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PLSM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.97B, about 2973.1x PLSM ($10.1M).
- DXCM has been more active in the news (14 items in the past 4 weeks vs 2 for PLSM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for PLSM).
- Company
- DexCom Inc.
- Pulsenmore Ltd.
- Price
- -
- -
- Market cap
- $29.97B
- $10.1M
- 1M return
- -5.54%
- -
- 1Y return
- +34.83%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 14
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest PLSM
- Chief Executive Officer Sonnenschein Elazar bought $15,740 worth of Ordinary Shares (9,259 units at $1.70) (SEC Form 4)
- SEC Form 4 filed by Pulsenmore Ltd.
- SEC Form 3 filed by Pulsenmore Ltd.
- SEC Form 4 filed by Pulsenmore Ltd.
- SEC Form 6-K filed by Pulsenmore Ltd.
- Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer
- SEC Form 6-K filed by Pulsenmore Ltd.
- Pulsenmore Expands Its Fertility Platform into the UK
- SEC Form 6-K filed by Pulsenmore Ltd.
- Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring